Modified immune cells aim to make stem cell transplants safer
NCT ID NCT06034535
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests a new method to improve stem cell transplants for people with blood disorders who lack a fully matched donor. Researchers will give patients specially processed donor immune cells (CD62L-depleted lymphocytes) alongside a T-cell depleted stem cell transplant. The goal is to reduce complications like graft failure and graft-versus-host disease, while improving survival. The study enrolls 23 participants and follows them for one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD62L-depleted donor lymphocytes
What this could lead to
If successful, this approach could reduce the risk of graft failure and severe graft-versus-host disease, making haploidentical transplants safer and more effective for patients without a matched donor.
What could go wrong
This is a small, early-phase trial (23 participants) testing a complex cell therapy. The treatment may not improve outcomes, and risks include infection, graft failure, or severe immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC ORGANS; DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hong Kong Children's Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••